XORTX THERAPEUTICS INC (XRTX.CA) Stock Price, Forecast & Analysis
Canada • TSX Venture Exchange • TSX-V:XRTX • CA98420Q3061
XRTX.CA Key Statistics, Chart & Performance
The current stock price of XRTX.CA is 0.68 CAD. In the past month the price decreased by -20%. In the past year, price decreased by -53.42%.
XRTX.CA Technical Analysis
XRTX.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to XRTX.CA. While XRTX.CA seems to be doing ok healthwise, there are quite some concerns on its profitability.
XRTX.CA Financial Highlights
Over the last trailing twelve months XRTX.CA reported a non-GAAP Earnings per Share(EPS) of -0.65. The EPS decreased by -1213.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -69.13% | ||
| ROE | -98.46% | ||
| Debt/Equity | 0 |
XRTX.CA Forecast & Estimates
XRTX.CA Ownership
XRTX.CA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| BHC | BAUSCH HEALTH COS INC | 1.33 | 2.881B | ||
| GSD | DEVONIAN HEALTH GROUP INC | N/A | 1.908B | ||
| CRON | CRONOS GROUP INC | 36.21 | 1.352B | ||
| TLRY | TILRAY BRANDS INC | N/A | 1.21B | ||
| DHT-UN | DRI HEALTHCARE TRUST | 7.23 | 914.275M | ||
| WEED | CANOPY GROWTH CORP | N/A | 589.536M | ||
| GUD | KNIGHT THERAPEUTICS INC | 122.77 | 584.818M | ||
| NGEN | NERVGEN PHARMA CORP | N/A | 422.97M | ||
| CPH | CIPHER PHARMACEUTICALS INC | 27.48 | 374.969M | ||
| TSND | TERRASCEND CORP | N/A | 346.155M |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the TSX Venture Exchange Exchange | Find stocks with similar TA and Setup ratings on the Canadian exchanges | Find stocks with similar Fundamental rating on the Canadian exchanges | Find the competitors with the best technical ratings on the Canadian exchanges | Find the competitors with the best fundamentals on the Canadian exchanges | Find the competitors with the best valuation on the Canadian exchanges | Find the competitors with the best dividend on the Canadian exchanges | Find the competitors with the best analyst ratings on the Canadian exchanges
About XRTX.CA
Company Profile
XORTX Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in Calgary, Alberta. The company went IPO on 2015-09-30. The firm is engaged in developing medications that improve the quality of life and health of individuals with gout and other important diseases. The company has three clinically advanced products in development: its lead program, XRx-026 program for the treatment of gout; XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD); and XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type II diabetic nephropathy. The company is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit the production of uric acid. The XRx-026 program is designed to decrease the chronically high serum uric acid concentration in the blood (SUA) by inhibiting the production of uric acid by the xanthine oxidase enzyme by administering a xanthine oxidase inhibitor-oxypurinol.
Company Info
XORTX THERAPEUTICS INC
3710 - 33rd Street NW
Calgary ALBERTA CA
Employees: 3
Phone: 14034557727
XORTX THERAPEUTICS INC / XRTX.CA FAQ
What does XORTX THERAPEUTICS INC do?
XORTX Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in Calgary, Alberta. The company went IPO on 2015-09-30. The firm is engaged in developing medications that improve the quality of life and health of individuals with gout and other important diseases. The company has three clinically advanced products in development: its lead program, XRx-026 program for the treatment of gout; XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD); and XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type II diabetic nephropathy. The company is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit the production of uric acid. The XRx-026 program is designed to decrease the chronically high serum uric acid concentration in the blood (SUA) by inhibiting the production of uric acid by the xanthine oxidase enzyme by administering a xanthine oxidase inhibitor-oxypurinol.
What is the stock price of XORTX THERAPEUTICS INC today?
The current stock price of XRTX.CA is 0.68 CAD.
What is the dividend status of XORTX THERAPEUTICS INC?
XRTX.CA does not pay a dividend.
What is the ChartMill technical and fundamental rating of XRTX stock?
XRTX.CA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the next earnings date for XRTX stock?
XORTX THERAPEUTICS INC (XRTX.CA) will report earnings on 2026-03-30, after the market close.